In a groundbreaking study poised to reshape our understanding of metastatic bladder cancer, researchers have uncovered a sophisticated signaling-metabolic circuit that co-opts the local muscle microenvironment to foster tumor spread. The study, spearheaded by Miaoling Tang’s team at Sun Yat-Sen University and published in the journal Targetome on February 13, 2026, illuminates the molecular cascade whereby tumor-secreted TGFβ3 induces mitochondrial metabolic rewiring in bladder smooth muscle cells (SMCs). These normally contractile cells accumulate succinate, an intermediary metabolite, which is then expelled as a paracrine factor, triggering a transdifferentiation process that converts muscle cells into endothelial-like vascular niche builders. This vascular remodeling not only facilitates intramuscular angiogenesis but also creates fertile grounds for disseminated tumor cells to seed distant metastases.
The clinical challenge addressed by this research stems from the stark prognostic shift observed once bladder tumors invade the detrusor muscle layer. Historically, clinicians have noted a precipitous rise in lymph node and systemic metastases after muscle invasion, yet the mechanistic “bridge” linking local invasion to systemic spread remained elusive. The detrusor consists predominantly of smooth muscle fibers, which possess a remarkable plasticity under pathological stimuli. The idea that tumor cells might “educate” these resident muscle cells to remodel their phenotype and the local blood vessel architecture reframes the invasion-metastasis paradigm, emphasizing a dynamic tumor-microenvironment crosstalk.
Using an integrative experimental approach that combined clinical pathology analysis, patient-derived bladder cancer models, advanced metabolomics, and targeted pathway interference, the investigators first quantified the density of microvessels within the muscularis layer of 305 archived bladder cancer specimens. Their findings revealed a significant elevation of intramuscular microvessel density (MVD) in muscle-invasive bladder cancer (MIBC) compared to non–muscle-invasive counterparts, aligning with poorer clinical outcomes such as decreased distant-metastasis–free and overall survival. Intriguingly, immunohistochemical analyses revealed that many CD31-positive vascular structures within the muscularis of MIBC co-expressed α-smooth muscle actin (α-SMA), a canonical smooth muscle marker. This unusual staining pattern suggested a vascular compartment partly derived from transformed SMCs.
Validating these clinical observations, the study employed an orthotopic xenograft mouse model using 15 patient-derived bladder cancer lines. Muscle-invasive lines robustly infiltrated the detrusor, induced prolific intramuscular vessel formation marked by dual positivity for CD31 and α-SMA, and produced lung metastases in the majority of cases. In contrast, non–muscle-invasive tumors remained confined to the superficial bladder layers, with sparse vascularization and no detectable metastatic dissemination. This model system powerfully linked muscle invasive behavior with vascular remodeling and metastatic progression.
To elucidate the tumor-derived factors orchestrating this muscle-to-endothelium phenotypic switch, the researchers developed co-culture systems combining human bladder smooth muscle cells (PBSMCs) with tumor-conditioned media. Fractionation experiments proved pivotal: the angiogenesis-inducing activity localized to small molecules below 3 kDa. Subsequent liquid chromatography-mass spectrometry (LC/MS) analysis identified succinate as vastly elevated in the active fraction. Importantly, exogenous addition of succinate to PBSMCs sufficed to drive loss of α-SMA and gain of endothelial markers such as CD31, CD144, and von Willebrand factor (vWF), effectively recapitulating the endothelial-like phenotype induced by tumor-conditioned media.
Mechanistic dissection revealed that the metabolic rewiring stemmed from a tumor-secreted ligand, transforming growth factor beta 3 (TGFβ3), which modulated the succinate metabolism enzyme sulfide:quinone oxidoreductase (SQOR). This axis resulted in succinate accumulation and its paracrine release. Time-resolved RNA sequencing and gene ontology analyses showed a biphasic transcriptional response in PBSMCs: an early wave characterized by suppression of smooth muscle genes, followed by subsequent induction of endothelial gene programs. Inhibitor studies pinpointed the activation of succinate receptor 1 (SUCNR1)-dependent MAPK/ERK signaling as a critical upstream event precipitating SMC dedifferentiation.
The translational impact of these findings is profound. The researchers outline multiple potential interventional nodes within this TGFβ3–SMAD2–SQOR–succinate signaling framework. Therapeutic strategies could encompass blockade of TGFβ3–SMAD2 signaling, inhibition of SQOR to prevent succinate accumulation, neutralization of extracellular succinate, or antagonism of SUCNR1 receptor signaling. Indeed, they demonstrated that administering a succinate-neutralizing antibody curtailed succinate-induced intramuscular angiogenesis in vivo, attenuating vascular niche formation. Moreover, targeting the interaction between SMAD2 and the transcription factor ETV4 with the bioactive compound L-chicoric acid successfully reduced hybrid vessels and suppressed lung metastasis in mouse models.
This mechanistic revelation also underscores a novel dimension of metabolic signaling in cancer progression, where a classical “intracellular” metabolite is commandeered as a secreted morphogen capable of cellular reprogramming within the tumor microenvironment. The conversion of contractile smooth muscle into pro-angiogenic, endothelial-like cells represents an unanticipated form of microenvironmental plasticity, directly linking metabolic state to phenotypic identity transitions conducive to metastasis.
Besides deciphering these molecular underpinnings, the study exemplifies the power of combining clinical specimen evaluation with patient-derived models and cutting-edge systems biology. The ability to recapitulate human muscle-invasive bladder cancer pathology and metastatic behavior in mice provided compelling validation of the clinical relevance and mechanistic insights gained. Equally noteworthy is the innovative integration of metabolomics with functional assays to identify succinate as a key paracrine mediator, opening avenues for metabolite-targeted therapies.
As muscle-invasive bladder cancer remains a formidable clinical challenge with limited therapeutic options beyond surgical resection and systemic chemotherapy, this work inspires hope for targeted approaches that disrupt the metastatic cascade at its earliest stages. By dismantling the vascular niches that tumors exploit for dissemination, such interventions may improve long-term survival and quality of life for afflicted patients.
Furthermore, the identification of L-chicoric acid as an inhibitor of the SMAD2–ETV4 interaction highlights natural product derivatives as promising chemical starting points for drug development. The capacity to interrupt transcriptional machinery driving succinate metabolic rewiring and endothelial reprogramming delineates a novel therapeutic paradigm in cancer.
In summary, this landmark study unravels a previously unappreciated signaling-metabolic axis commandeered by bladder tumors to reprogram local smooth muscle cells, fostering a pro-metastatic vascular microenvironment. The elucidated TGFβ3–SMAD2–SQOR–succinate loop not only advances our fundamental understanding of bladder cancer biology but also unveils actionable molecular targets with translational promise. As research continues to dissect tumor- stromal interactions and metabolite signaling networks in other malignancies, this framework may provide broad insights applicable across cancer types.
Subject of Research:
Not applicable
Article Title:
TGFβ3-SMAD2/ETV4/CARM1 axis drives metastatic progression in Muscle-invasive Bladder Cancer via succinate metabolic rewiring
News Publication Date:
13-Feb-2026
Web References:
http://dx.doi.org/10.48130/targetome-0026-0007
References:
10.48130/targetome-0026-0007
Keywords:
Bladder cancer, Muscle-invasive bladder cancer, TGFβ3, SMAD2, Succinate metabolism, Smooth muscle cell plasticity, Metastasis, Vascular niche, SUCNR1, SQOR, Tumor microenvironment, Angiogenesis
